Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma

European Cytokine Network

Volumn 17, Issue 1, 2006, Pages 60-66

  Lech Maranda, Ewa ^a,b   Bienvenu, Jacques ^a,c   Michallet, Anne Sophie ^c   Houot, Roch ^c   Robak, Tadeusz ^b   Coiffier, Bertrand ^a,c   Salles, Gilles ^a,c  

^a UNIVERSITÉ LYON 1   (France)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Interleukin 10; International Prognostic Index; Lymphoma

Indexed keywords

INTERLEUKIN 10;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLOOD; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INTERLEUKIN-10; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 33746083294     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M. The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 2004; 15: 61.
2. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683.
3. Benjamin D, Knobloch TJ, Dayton MA. Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood 1992; 80: 1289.
4. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH, Kastelein R, Moore KW, Banchereau J. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992; 89: 1890.
5. Levy Y, Brouet JC. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 1994; 93: 424.
6. Blay JY, Burdin N, Rousset F, Lenoir G, Biron P, Philip T, Banchereau J, Favrot MC. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 1993; 82: 2169.
7. Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kurzrock R. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood 1995; 85: 2516.
8. Ozdemir F, Aydin F, Yilmaz M, Kavgaci H, Bektas O, Yavuz MN, Yavuz AA. The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL). J Exp Clin Cancer Res 2004; 23: 485.
9. Stasi R, Zinzani PL, Galieni P, Lauta VM, Damasio E, Dispensa E, Dammacco F, Papa G, Tura S. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br J Haematol 1994; 88: 770.
10. Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989; 7: 1018.
11. Huhn RD, Radwanski E, O'Connell SM, Sturgill MG, Clarke L, Cody RP, Affrime MB, Cutler DL. Pharmacokinetics and immunomodulatory proporties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 1996; 87: 699.
12. Geissler K, Öhler L, Fodinger M, Kabrna E, Kollars M, Skoupy S, Lechner K. Interleukin-10 inhibits erytropoietin-independent growth of erythroid bursts in patients with polycythemia vera. Blood 1998; 92: 1967.
13. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235.
14. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, Bouabdallah R, Reyes F, Gaulard P, Coiffier B. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279.
15. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by Rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001; 7: 709.
16. Westendorp RG, Langermans JA, Huizinga TW, Verweij CL, Sturk A. Genetic influence on cytokine production in meningococcal disease. Lancet 1997; 349: 170.
17. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000; 181: 176.
18. Bertorello R, Cordone MP, Contini P, Rossi P, Indiveri F, Puppo F, Cordone G. Increased levels of interleukin-10 in saliva of Sjogren's syndrome patients. Correlation with disease activity. Clin Exp Med 2004; 4: 148.
19. Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun 2001; 1: 185.
20. Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, Kurzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001; 97: 2560.
21. Sarris AH, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C, Messina O, Pugh W, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Witzig T, Duvic M, Andreeff M, Cabanillas F. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 1999; 10: 433.
22. Bohlen H, Kessler M, Sextro M, Diehl V, Tesch H. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol 2000; 79: 110.
23. Visco C, Vassilakopoulos TP, Kliche KO, Nadali G, Viviani S, Bonfante V, Medeiros LJ, Notti P, Rassidakis GZ, Peethambaram P, Wilder R, Witzig T, Gianni M, Bonadonna G, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH. Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. Leuk Lymphoma 2004; 45: 2085.
24. Viviani S, Notti P, Bonfante V, Verderio P, Valagussa P, Bonadonna G. Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the Milan Cancer Institute experience. Med Oncol 2000; 17: 59.
25. Vassilakopoulos TP, Nadali G, Angelopoulou MK, Siakantaris MP, Dimopoulou MN, Kontopidou FN, Rassidakis GZ, Doussis-Anagnostopoulou IA, Hatzioannou M, Vaiopoulos G, Kittas C, Sarris AH, Pizzolo G, Pangalis GA. Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica 2001; 86: 274.
26. Axdorph U, Sjoberg J, Grimfors G, Landgren O, Porwit-MacDonald A, Bjorkholm M. Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease. Ann Oncol 2000; 11: 1405.
27. Urbańska-Ryś H, Wierzbowska A, Stepień H, Robak T. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM) and soluble interleukin-6 receptor (sIL-6R) in patients with multiple myeloma. Eur Cytokine Netw 2000; 11: 443.
28. Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, Warzocha K, Coiffier B, Salles S. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004; 103: 3529.
29. Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab I, Favrot MC, Blay JY. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996; 56: 5499.
30. Fluckiger AC, Durand I, Banchereau J. Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells. J Exp Med 1994; 179: 91.
31. Cervenak L, Morbidelli L, Donati D, Donnini S, Kambayashi T, Wilson JL, Axelson H, Castanos-Velez E, Ljunggren HG, Malefyt RD, Granger HJ, Ziche M, Bejarano MT. Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Blood 2000; 96: 2568.